NHS approves teplizumab for type 1 diabetes delay amid systemic gaps in prevention and equity
Original framing: “Drug that delays onset of type 1 diabetes approved in England and Wales” — The Guardian - World
Teplizumab’s mechanism—modulating T-cell activity—is well-documented, but its long-term efficacy and side effects remain understudied in diverse populations. Emerging research implicates environmental pollutants (e.g., PFAS, BPA) and gut microbiome disruption in type 1 diabetes pathogenesis, yet these factors are excluded from clinical trials. The drug’s approval prioritizes short-term marketable solutions over systemic scientific inquiry.
The approval of teplizumab reflects a biomedical paradigm that treats type 1 diabetes as an individual defect rather than a systemic failure of industrial food systems, environmental policy, and colonial health practices.
Indigenous and Afro-diasporic knowledge systems offer time-tested solutions—from agroecology to spiritual practices—that are systematically excluded in favor of patented drugs, reinforcing corporate and colonial power structures. Historical patterns show that crises like diabetes emerge from ecological disruption and cultural erasure, yet mainstream solutions prioritize marketable fixes over structural change. The trickster’s lens reveals the absurdity of celebrating a three-year delay while ignoring the root causes of a preventable epidemic. True progress demands integrating ancestral wisdom, environmental justice, and community-led care into healthcare systems, ensuring that solutions are equitable and regenerative rather than extractive.